Multiple Sclerosis Research:
PASSAGE – Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
This study is for patients with relapsing forms of MS, who are newly starting treatment with Gilenya (fingolimod) at the beginning of their trail participation. Participants are only asked to attend their normal office visits, from which anonymous medical information is taken to contribute to an ongoing safety analysis of this medication. Enrolled patients will have our office visits paid for by the study until 2022, but don’t wait, enrollment ends in November of 2017!
Learn more about PASSAGE
AbbVie M14-173 – A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
Patients who are currently not on treatment for their relapsing Multiple Sclerosis, or have been on a steady dose of an oral or injectable treatment for at least 3 months may be eligible for this trial. AbbVie Inc., a pharmaceutical company, has set out to see if their experimental treatment “ABT-555” is a safe and effective way to further fight the effects of this disease. The treatment is via 4 infusions, and participants would randomly receive one of three dose strengths or a placebo.
IDEAS – Imaging Dementia—Evidence for Amyloid Scanning Study
The purpose of this study is to assess the impact of amyloid PET scans, which are useful to diagnose Alzheimer’s disease and other types of dementia, on patient outcomes. Those eligible must be 65 years of age or older and have Medicare Part B or C as their primary insurance. The goal of the study is to find if amyloid PET scans will decrease uncertainty and increase confidence in the underlying cause of cognitive impairment or dementia, which could translate into earlier counseling and interventions in these domains and potentially lead to better outcomes. Amyloid PET scans have been approved by the FDA, but are expensive and currently not covered by insurance. This trial offers this scan at a tremendously reduced cost, or even for free depending on your secondary insurance plan!
Learn more about IDEAS
AWARE – A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer’s Disease
The purpose of the AWARE trial is to determine the efficacy and safety of an experimental treatment (ABBV-8E12) for patients with Alzheimer’s disease. For those who qualify to participate, ABBV-8E12 treatments would be administered through an IV infusion once a month for two years in our office. This study is testing three dose strengths compared to placebo, so participants have a 75% chance of receiving the treatment. Enrolled patients will have the medication and office visits paid for during the study, and will be generously compensated for their time!
Learn more about AWARE
Neurogenic Orthostatic Hypotension (NOH) Research:
RESTORE – Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension
The purpose of this study is to evaluate the efficacy and safety of Northera (droxidopa) to treat neurogenic orthostatic hypotension (NOH). NOH symptoms include dizziness, light-headedness, or feelings that you may black out upon standing. This medication is for patients who also have Parkinson’s Disease (PD), Multiple System Atrophy (MSA), Pure Autonomic Failure (PAF), Non-Diabetic Autonomic Neuropathy (NDAN) or Dopamine Beta-Hydroxylase (DBH) deficiency. Northera has been approved by the FDA, and participants will receive medication and office appointments paid for during the study, as well as compensation for participation and travel expenses!
Learn More about RESTORE
703-313-9111 ext. 107
Study sponsors: Our office is interested in further expansion and diversification of our clinical trials so that we can offer these opportunities to more of our patients. If you are currently recruiting sites for any clinical trial pertaining to a neurological condition that does not compete with our current trials, feel free to call or email Lindsay with information!